- Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Hidalgo, M., Siu, L.L., Nemunaitis, J., Rizzo, J., Hammond, L.A., Takimoto, C., Eckhardt, S.G., Tolcher, A., Britten, C.D., Denis, L., Ferrante, K., Von Hoff, D.D., Silberman, S., Rowinsky, E.K. J. Clin. Oncol. (2001)